Introduction {#sec1_1}
============

The management of patients with cancer during the current pandemic of COVID-19 is challenging. As of March 30, 2020, more than 690,000 confirmed cases and more than 33,000 deaths have been documented worldwide \[[@B1]\]. Cancer patients require special attention, as decisions regarding treatment during the current pandemic require specialized consideration. The quality of care for cancer patients has been affected during this pandemic \[[@B2], [@B3], [@B4], [@B5]\] and strategies are required to deliver the best care. From a nationwide analysis in China, 18 (1%) out of 1,590 COVID-19 cases had a history of cancer \[[@B6]\]. Patients with cancer were more likely to be older and had more frequently abnormal computed tomography (CT) scans. More significantly, patients with cancer infected with coronavirus were more likely to have an adverse event defined as admission to the intensive care unit requiring ventilation or death (39 vs. 8%, *p* = 0.0003). Cancer patients also had a shorter median time to severe events (13 vs. 43 days, *p* \< 0.0001). Cancer, as a variable, had the highest odds ratio \[[@B5], [@B3]\] for having adverse events. Despite the limitation of a small sample size and the heterogeneity of cancer patients, these results are concerning. Cancers differ in their pathogenesis and the urgency of starting treatment is not the same for all cancers. We report our personal opinions regarding the management of patients with multiple myeloma (MM) during this challenging time. The reader is advised that these recommendations are based on experience and are not evidence based.

What Is Special about MM Patients? {#sec1_2}
==================================

The immune system in patients with MM is compromised by many different factors and patients with MM are at increased risk of infection \[[@B7]\]. The mean age at diagnosis for myeloma is approximately 65 and elderly patients are more likely to have comorbidities compromising the immune system. Lymphopenia at diagnosis is a well-known risk factor for developing infections \[[@B8], [@B9], [@B10]\]. This is a result of the myeloma clone suppressing normal B-cell development and function. A loss of functional immunoglobulins seen in most myeloma patients can also contribute to the increased risk of infection. Decreased CD+4 T-cell count at diagnosis is also associated with increased infections \[[@B11], [@B12]\]. Patients with MM receive treatment that causes more immunosuppression and increases the risk of infection \[[@B13]\]. Lymphopenia worsens after starting therapy for MM \[[@B10]\] and CD4 counts decrease with proteasome inhibitor (PI) therapy \[[@B14]\], and the risk of zoster reactivation is up to 13% without prophylaxis \[[@B15]\]. Immunomodulatory drugs (IMiDs) cause neutropenia, which increases the infection risk. Steroids are well known to increase the risk of infections (including pneumocystis and fungus) and the combination with IMiDs and PIs increases this further. The infection risk is highest during the first 3--4 months of therapy. Prophylactic levofloxacin for 12 weeks in newly diagnosed myeloma has been shown to reduce deaths significantly \[[@B16]\]. All of the previous factors make MM patients more susceptible to the serious adverse events that could arise with COVID-19 infection. COVID-19 can intensify neutropenia \[[@B17]\].

What Is Our Approach to Smoldering MM? {#sec1_3}
======================================

There is no disagreement regarding the management of standard-risk smoldering MM (SMM) patients. These patients should be monitored with no active intervention. For high-risk SMM based on the Mayo 2018 risk stratification \[[@B18]\], experts differ in their approach. Two phase III randomized trials evaluated the use of active therapy for SMM, one with lenalidomide and dexamethasone \[[@B19]\]and the other with lenalidomide alone \[[@B20]\]. There was improvement in progression-free survival (PFS) in 2 trials \[[@B19], [@B20]\] and overall survival (OS) in 1 trial \[[@B19]\]. However, both trials had several limitations. In both trials, the sample size was less than 100 patients in each arm. In the Spanish myeloma group trial \[[@B19]\], imaging was done using X-ray, which is less sensitive than current diagnostic modalities (including low-dose CT skeletal survey and PET scans), and the benefit of survival in some patients could have been due to treating active MM (normal radiographs but abnormal PET or MRI), rather than SMM. In the second trial, there is no OS benefit to date and only 30% were high risk according to the Mayo 2018 risk stratification \[[@B20]\]. Also, 3.3% of patients had bone marrow plasma cells ≥60 and 8.2 % had serum-free light chains \>100 mg/dL which are MM defining events by definition \[[@B20]\]and these patients may have been randomized to no therapy.

We currently believe that involving patients in a clinical trial is the best strategy for high-risk SMM patients. However, with the current COVID-19 pandemic, many trials are not accepting new patients and we would advise close monitoring and observation for these patients.

What Is Our Approach to Newly Diagnosed Patients? {#sec1_4}
=================================================

Risk Stratification {#sec2_1}
-------------------

MM is a heterogeneous malignancy and patients behave differently. Risk stratification is critical, especially during the current COVID-19 situation. In general, patients with trisomies, t(11;14), or t(6;14) are considered standard risk. High-risk genetic abnormalities include t(4;14), t(14;16), t(14;20), 17p del, 1q+ and p53 mutations. The Revised International Staging System (R-ISS) \[[@B21]\] defines patients with stage III as high risk. Patients with extramedullary disease are also considered high risk. We consider patients with plasma cell leukemia (PCL) as ultra-high risk.

Screening for COVID-19 before Starting Therapy {#sec2_2}
----------------------------------------------

We recommend screening all patients with newly diagnosed MM for COVID-19 before starting therapy, as treatment for MM can aggravate the adverse events of an active COVID-19 infection. Screening should be done for outpatients as well as inpatients initiating therapy.

For patients testing positive for COVID-19 we recommend holding treatment until they have convalesced from acute illness. Metabolic and bone-related acute complications can be best managed with supportive care.

Patient and Family Member Education {#sec2_3}
-----------------------------------

Prevention is the best cure. We stress educating the patient about the impact of COVID-19 on their health, emphasizing the weak immune system in patients with MM. Social distancing, staying home (except for treatment), washing hands frequently with soap (for at least 20 s), covering coughs and sneezes with tissue or using the elbow, and cleaning frequently touched surfaces are recommended \[[@B22]\].

Family members are critical for patient care and their mental health is important. Social support including tips for coping with stress should be provided to the patient and their family members. We find the following website (<https://suicidepreventionlifeline.org/current-events/supporting-your-emotional-well-being-during-the-covid-19-outbreak/>) useful in providing recommendations regarding coping with the current pandemic \[[@B23]\].

What Regimen? {#sec2_4}
-------------

### For Standard-Risk Patients {#sec3_1}

We believe that these patients could be managed using oral drugs to decrease the risk of weekly hospital visits and exposures. We recommend ixazomib, lenalidomide, and dexamethasone (IRd) given over a 28-day cycle. Lenalidomide should be given at a dose of 25 mg p.o. daily on days 1--21 and ixazomib at a dose of 4 mg p.o. on days 1, 8, and 15. We recommend decreasing the dose of dexamethasone to 20 mg p.o. weekly to decrease the risk of infection. We understand that the IRd regimen has not been compared head to head with known standard therapy, but the response rate from the phase 1/2 trial is comparable \[[@B24]\] and in our opinion using an oral regimen will help in decreasing the exposure to and infection with COVID-19.

Another possible combination is cyclophosphamide lenalidomide and dexamethasone (CRd) given over a 28-day cycle \[[@B25]\] with cyclophosphamide (300 mg/m^2^ p.o. on days 1, 8, and 15), lenalidomide (25 mg p.o. on days 1--21), and dexamethasone (20 mg p.o. daily once weekly).

A third alternative is daratumumab lenalidomide and dexamethasone (DRd) given over a 28-day cycle \[[@B26]\]. Full doses of daratumumab and lenalidomide should be given. We would recommend that the first dose of dexamethasone is 40 mg p.o. to decrease the risk of infusion-related reaction to daratumumab. We would recommend giving dexamethasone orally, rather than intravenously, to decrease the total time in the chemotherapy unit for the patient. The dose of dexamethasone can be decreased during subsequent cycles, if no infusion reaction is documented. If no infusion reactions occur, the interval for daratumumab infusion can be decreased to 90 min.

We understand that not all patients can access these medications. In that case, standard of care therapy using lenalidomide, bortezomib, and dexamethasone (RVd) should be considered. We would recommend RVd over 28 days with lenalidomide (25 mg p.o. on days 1--21), bortezomib (1.5 mg/m^2^ s.c. on days 1, 8, and15), and dexamethasone (20 mg p.o. daily once weekly). We want to stress the point that bortezomib should be given subcutaneously once a week, rather than intravenously or twice weekly. In some countries, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is the only approved combination for initial therapy. We again would recommend bortezomib to be given subcutaneously once a week and the dose of dexamethasone reduced to 20 mg.

### For High-Risk Patients {#sec3_2}

Patients with high-risk features have a different biology and the management of these patients can be very challenging. We believe these patients have a greater risk of morbidity from myeloma than COVID-19 infection justifying weekly clinic visits for therapy, while in standard-risk patients an all oral regimen allows for therapy visits every 4 weeks. For high-risk patients, we would recommend carfilzomib, lenalidomide, and dexamethasone (KRd) given over 28 days for each cycle. We do not believe there is a high risk for tumor lysis syndrome with MM and we would recommend starting therapy for the first cycle with once-weekly dosing, rather than doing day 1 and day 2 infusions. If the patient has good bone marrow reserve, we would recommend carfilzomib at 70 mg/m^2^ i.v. on days 1, 8, and 15, lenalidomide 25 mg p.o. on days 1--21, and dexamethasone 20 mg p.o. once weekly. If there are concerns regarding cytopenias, we would recommend carfilzomib at a dose of 56 or 36 mg/m^2^ i.v. (as appropriate) on days 1, 8, and 15. If KRd is not available, we would recommend RVd, as above.

Supportive Management {#sec2_5}
---------------------

Supportive measures are invaluable for patients with MM. IMiDs increase the risk of venous thromboembolism and prophylactic anticoagulation is needed. We recommend aspirin (325 mg p.o. daily) for patients with no other risk factors for venous thromboembolism. Other forms of anticoagulation are required in higher-risk patients. Prophylaxis against varicella-zoster virus (acyclovir 400 mg p.o. b.i.d. daily) is required for patients on PIs. For *Pneumocystis jirovecii* prophylaxis, we would recommend using single-strength trimethoprim-sulfamethoxazole given daily or double strength given on Monday, Wednesday, and Friday. If the patient cannot safely receive sulfa, we would recommend using prophylaxis other than pentamidine, as its administration requires a clinic visit and the fact that it is an aerosolized therapy could be a concern with the current COVID-19 pandemic.

For bone disease prophylaxis, we believe that it can be delayed, especially in patients without active bone disease. If a patient has diffuse bone disease or has hypercalcemia, then we would recommend using zoledronic acid. For bone prophylaxis, this can be given every 3 months, rather than monthly. Patients should be advised to take calcium and vitamin D.

We do not recommend using growth factors. If a patient requires it, we would recommend using pegfilgrastim, if possible.

Lab Work and Follow-Up {#sec2_6}
----------------------

We would recommend decreasing the frequency of blood work during each cycle as much as possible. If the patient has good bone marrow reserve, blood work can be done after finishing the cycle (before starting the next cycle), rather than checking counts routinely every week during the first cycle. We also recommend follow-up using telehealth technologies (telephone calls, video, etc.).

Drug companies have extended the supply of lenalidomide and pomalidomide to 8 weeks with drugs being shipped home, rather than requiring a visit to a specialized pharmacy. This will help reduce potential exposure to COVID-19.

The Hot Question: Should We Do Autologous Stem Cell Transplant after Induction? {#sec2_7}
-------------------------------------------------------------------------------

Autologous stem cell transplant (ASCT) clearly improves outcomes in newly diagnosed MM patients. However, during this challenging time, each patient should be evaluated individually. Multiple trials have evaluated upfront versus delayed ASCT and overall, upfront ASCT improves PFS, but not OS \[[@B27], [@B28], [@B29], [@B30], [@B31]\]. The two main concerns with the current COVID-19 pandemic is that patients need their stem cells collected and some patients require more than one apheresis. With conditioning comes the increased risk of infection related to the 7--9 days of severe neutropenia.

### Standard-Risk Patients {#sec3_3}

For standard-risk patients who are responding well to therapy, we would recommend delaying ASCT until the current situation with COVID-19 improves. Continued induction therapy can safely be used as a bridge until the epidemic subsides \[[@B32]\].

### High-Risk Patients {#sec3_4}

For high-risk patients, if they are responding (at least with partial response) ASCT can be delayed. However, patients who are not responding or progressing quickly, ASCT can be considered as salvage therapy. Testing for COVID-19 should be done before ASCT. Balancing the risks of COVID-19 infection and MM-related mortality is difficult. Consultation with a MM expert is recommended.

Ultra-High-Risk Patients (PCL) {#sec2_8}
------------------------------

These are the most challenging patients during the current pandemic. The median OS in these patients is less than a year with current treatment approaches \[[@B33]\]. We believe that induction chemotherapy followed by ASCT should be done for these patients, as the risk of progressive disease is high. Testing for COVID-19 should be done before ASCT.

Any Concerns for Collecting Stem Cells Later? {#sec2_9}
---------------------------------------------

There are no major concerns for collection, as patients receiving IMiD-based therapy can successfully undergo stem cell collection after 6 cycles \[[@B34]\] using granulocyte colony-stimulating factor (G-CSF). For patients who fail to collect using G-CSF, plerixafor can be used.

Delaying stem cell collection is wise, especially in patients who had a recent COVID-19 infection. Hyperimmunity with cytokine storms and acute respiratory distress syndrome from the infection has been described \[[@B35], [@B36]\]. In theory G-CSF can reinitiate the immune stimulus leading to complications.

How Many Cycles Should We Give/Any Dose Modifications? {#sec2_10}
------------------------------------------------------

In general, we would recommend continuing with treatment until the current epidemic with COVID-19 improves and ASCT is safer.

### Standard-Risk Patients {#sec3_5}

Patients who achieve sustained very good partial response or better (≥VGPR) after 3--4 cycles, the doses of dexamethasone should be decreased further to 12 mg with monitoring of response. If the concerns regarding COVID-19 continue, and the patient is on bortezomib, the frequency of administration can be decreased to every other week after 6--8 cycles (if response is ≥VGPR and is sustained). If the patient is on daratumumab-based therapy (DRd) and has achieved ≥VGPR after the second cycle, we would recommend continuing the cycle every 28 days, but change the daratumumab to every 4 weeks rather than every 2 weeks. After 10--12 cycles and if the goals of therapy are achieved, switching to maintenance therapy with lenalidomide can be considered.

### High-Risk Patients {#sec3_6}

Overall, we believe that these patients should continue on their triplet therapy for 10--12 months. The dose of dexamethasone can be decreased after 4--6 cycles if sustained deep responses (≥VGPR) are achieved. The frequency of PIs can be reduced to every 2 weeks, if the response is sustained. After 10--12 cycles, we would recommend PI-based maintenance with bortezomib subcutaneously every 2 weeks or weekly ixazomib. Those patients should undergo ASCT as soon as the pandemic resolves.

Special Population: Frail/Non-Transplant-Eligible Patients {#sec2_11}
----------------------------------------------------------

If DRd is available, we would recommend it for these patients if weekly clinic visits are feasible and safe. If not, using a triplet, such as IRd (preferred), CRd, RVd, or CyBorD can also be considered, depending on availability. These patients frequently require dose adjustments and close monitoring is recommended.

What Is Our Approach to Progressing/Relapsing Patients? {#sec1_5}
=======================================================

Most patients with MM will relapse and the management of relapse should be individualized depending on the patient, as not all relapses biologically behave the same. A discussion regarding the management of relapsed MM patients is beyond the scope of this review. We recommend viewing the mSMART guidelines from our institution \[[@B37]\]. Key points are described below:

Standard-Risk Patients {#sec2_12}
----------------------

For those patients who relapse late from diagnosis with no high-risk genetic features and who did not receive daratumumab as part of the induction, we would recommend daratumumab-based regimens. If the patient responds well and is stable, recommendations regarding dose adjustment can be followed as for newly diagnosed patients (above). We would not recommend proceeding directly with ASCT (if it was part of the treatment plan) until the current pandemic resolves. If daratumumab is not available, other triplet combinations should be used depending on availability, fitness of the patient, and type of maintenance therapy. If the patient is not responding well and is failing conventional therapy, ASCT can be considered as salvage. A reminder: these patients should be screened for COVID-19 before ASCT.

High-Risk Patients {#sec2_13}
------------------

These patients are the most difficult to manage with the current situation. The management will depend on the nature of relapse and how aggressive it is. Again, if patients did not receive daratumumab, daratumumab-based treatment should be used. If daratumumab is not available, other triplet combinations should be considered depending on availability, fitness of the patient, and type of maintenance therapy.

The decision regarding ASCT should be individualized. For patients with aggressive relapse (especially with suboptimal responses to salvage therapy), ASCT should be considered as salvage. These patients should be screened for COVID-19 before ASCT. For patients who relapse slowly and achieve deep responses (≥VGPR) after therapy, ASCT should be delayed.

Ultra-High-Risk Patients {#sec2_14}
------------------------

Patients with secondary PCL (in the setting of refractory/relapsed MM) have a grim prognosis \[[@B38]\]. These patients should receive myeloma-directed therapy followed by ASCT. Testing for COVID-19 should be done before ASCT.

What Is Our Approach to Stable Myeloma Patients on Maintenance? {#sec1_6}
===============================================================

We believe that patients who are stable on maintenance with no major side effects should continue on their maintenance. If the patient is on dexamethasone during their maintenance, we recommend tapering it down with the goal of discontinuing it. These patients do not need to be seen in clinic for 3 months. Monitoring should occur in the closest laboratory and phone visits may be used for toxicity checks.

How about Clinical Trials? {#sec1_7}
==========================

In many centers clinical trials have been suspended for new patients because the requirements for testing lead to frequent protocol violations. Some clinical trials are modifying their protocols, allowing blood draws to be done locally, telemedicine evaluation, and oral drugs to be shipped home.

Conclusions {#sec1_8}
===========

The management of patients with MM during the current pandemic of COVID-19 is challenging. We do not recommend any active therapy for SMM patients, standard or high risk. Patients with active MM should be risk stratified before treatment. Screening for COVID-19 should be done for all patients (in patients and outpatients) before starting therapy. For standard-risk patients options include: IRd (preferred), CRd, DRd, RVd, or CyBorD. For high-risk patients KRd (preferred) or RVd are options. We recommend decreasing the dose of dexamethasone to 20 mg p.o. once weekly and the PIs should be given once weekly with bortezomib being given subcutaneously. Supportive management with antibiotics and anticoagulants (as needed) is critical. We recommend delaying ASCT, unless the patient has high-risk disease that is not responding well, or if the patient has PCL. Testing for COVID-19 should be done before any ASCT or new chemotherapy regimen. Doses and frequency of drug administration can be modified, especially in patients with ≥VGPR that is sustained. After 10--12 cycles, maintenance can be started with lenalidomide for standard-risk patients and bortezomib or ixazomib for high-risk patients. For relapsed patients, daratumumab-based regimens should be considered. We would recommend ASCT for patients with aggressive relapse, as well for patients with secondary PCL. Patients on maintenance should continue their therapy. In many centers clinical trials have been suspended as a result of the current pandemic with COVID-19.
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